Showing 3 posts of 3 posts found.


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

May 30, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …

AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …


Roche’s satralizumab succeeds in second positive study in rare CNS disease

September 12, 2019
Research and Development NMOSD, Roche, satralizumab

In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …

Latest content